GN ReSound launches hearing aid compatible with Apple’s iPhone, iPad and iPod
COPENHAGEN, Denmark — GN ReSound recently launched its ReSound LiNX in global markets as a hearing aid capable of streaming high-quality stereo sound from an iPhone, iPad and iPod touch without the need for an additional pendant-like device. Users can also customize their hearing experience through the ReSound Smart App.
“We saw an opportunity to create the world’s best hearing aid by combining the capability of GN ReSound’s life-changing technologies with the compatibility and global prevalence of iPhone, iPad and iPod touch,” stated GN ReSound CEO Lars Viksmoen. “We are committed to improving people’s lives through use of innovative technology and look forward to more people correcting their hearing with this new technology — a triumph in accessibility for the hearing impaired.”
ReSound LiNX incorporates a number of ReSound technologies, including:
- ReSound LiNX applies a version of Surround Sound by ReSound – an integrated sound processing technology;
- ReSound LiNX is a Made for iPhone hearing aid that offers direct streaming of sound from iPhone, iPad and iPod touch, allowing wearers to utilize their hearing aids to talk on the phone and listen to music in high-quality stereo sound without the need for an additional remote control, accessory or pendant;
- The accompanying ReSound Smart App allows users to set preferred volume levels as well as treble/bass settings, and use geo-tagging to assign and adjust to the acoustics of frequently visited places like home, work and favorite restaurant, among other locations;
- ReSound Smart also features a ‘Find My Hearing Aid’ function to help users pinpoint their hearing aids if misplaced;
- ReSound LiNX is the smallest wireless Receiver-in-the-Ear hearing aid brought to market by GN ReSound, yet powerful enough to address 90% of all hearing losses; and
- GN ReSound’s unique 3rd generation 2.4 GHz wireless technology, based on the all new SmartRange chipset, is the foundation of this latest technological breakthrough. ReSound LiNX is the first hearing aid on the market to integrate SmartRange with Bluetooth Smart technology.
Study: Omega-3 fatty acids EPA and DHA help lower blood pressure
SALT LAKE CITY — A study published online Friday shows that the omega-3 fatty acids EPA and DHA — commonly found in fatty fish and fish oil supplements — are as effective, if not more effective, in lowering blood pressure as some of the commonly recommended lifestyle changes like increasing physical activity and restricting alcohol and sodium intake. The findings, released by the American Journal of Hypertension, are good news, especially for those with elevated blood pressure.
The study was funded by the Global Organization for EPA and DHA Omega-3s (GOED), which has submitted an authorized health claim petition to the Food and Drug Administration based on these results.
"Results from this study build on a wealth of prior data indicating that EPA+DHA intake reduced the risk of cardiovascular events," stated Adam Ismail, executive director of GOED. “It is now well-established that EPA and DHA reduce triglycerides and blood pressure and even highly critical meta-analyses have found that they reduce cardiac death risk by 9%."
The study, a comprehensive meta-analysis, examined 70 randomized controlled trials, conducted with adults who were given EPA+DHA omega-3s from seafood, fortified foods or dietary supplements. The study included trials with subjects with normal blood pressure and those with hypertension but not taking blood pressure-lowering medications.
The most significant effects were observed in subjects with existing high blood pressure. Among those with high blood pressure, the average decrease in systolic blood pressure was 4.51 mm Hg and diastolic blood pressure was reduced by an average 3.05 mm Hg.
“When measuring blood pressure, even small reductions can have a significant clinical impact,” stated Dominik Alexander, senior author of the study. According to Stamler, each 2 mm Hg reduction reduces stroke mortality by 6%, coronary heart disease mortality by 4% and total mortality by 3%.
Alexander noted that a decrease in SBP of 1.25 mm Hg could prevent a pre-hypertensive from becoming hypertensive. “A decrease of 4.51 mm Hg in SBP among those with high blood pressure could help an individual avoid having to take medication to control blood pressure levels,” he added.
SoloHealth realigns to focus on wellness plans for major employers
DULUTH, Ga. — As part of a realignment to "focus on wellness plans for major employers," SoloHealth founder Bart Foster has stepped down as CEO of the company to assume a new role as chief strategy officer, according to a report in the Atlanta Business Chronicle published Thursday.
Chairman Larry Gerdes will assume the role of CEO. The move will capitalize on the strengths of Foster — sales and strategy — Gerdes told the Chronicle.
SoloHealth most recently signed Health Care Service Corporation in a partnership to help promote SoloHealth offerings to consumers in three of the states where it operates. The partnership gives HCSC unique access to SoloHealth’s network of health and wellness consumer kiosks to conduct brand advertising and targeted new-member acquisition campaigns.
The news comes on the heels of several health care insurer partnership announcements for SoloHealth, including recent deals with the Department of Health & Human Services, eHealth and Blue Cross Blue Shield of Georgia.
Executives expect to announce additional partnerships this fall.